Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib open-label dose-escalation study of BI 907828 in advanced or metastatic solid tumors
jRCT2080223999Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of brigimadlin in Nonhematologic neoplasms, Bone and soft tissue sarcoma, non-small cell lung cancer (NSCLC) and 4 more (3 arms), sponsored by Boehringer Ingelheim. Started Aug 2018; status: completed.
02
Drugs
brigimadlin
03
Conditions
Nonhematologic neoplasmsBone and soft tissue sarcomanon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2080223999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223999.